Related Experiment Videos

[The treatment of acute myocardial infarct with perlinganit]

Terapevticheskii Arkhiv
|January 1, 1990
PubMed

Insights

Perlinganit effectively treats acute myocardial infarction by improving hemodynamics and reducing symptoms. This study shows its advisability for patients with heart attacks.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Acute myocardial infarction (MI) is a leading cause of mortality.
  • Left ventricular insufficiency and arrhythmias are common complications of MI.
  • Current treatments aim to restore blood flow and manage complications.

Purpose:

  • To evaluate the clinical and hemodynamic effects of Perlinganit in patients with acute myocardial infarction.
  • To assess the antianginal and antiarrhythmic properties of Perlinganit during MI treatment.

Summary:

  • A study observed 43 patients with acute myocardial infarction (30 men, 13 women, aged 36-82).
  • Perlinganit was administered via a drug-dosing apparatus (DDA-1) at an average infusion rate of 74.5 ± 3.4 µg/min for 51.1 ± 4.8 hours.
  • Significant clinical and hemodynamic improvements were noted, including elimination of left ventricular insufficiency and normalization of contractile function within hours.
  • Antianginal and antiarrhythmic effects were observed during treatment.

Impact:

  • Perlinganit demonstrated significant efficacy in managing acute myocardial infarction.
  • The drug improved hemodynamic parameters and alleviated clinical symptoms.
  • Findings suggest Perlinganit is a recommendable therapeutic option for acute myocardial infarction.

Related Concept Videos